The resulting PA variants, such as the MMP-activated PA-L1 and the uPA-activated PA-U2, can be used to selectively deliver effector proteins, LF and LF fusions, into tumor tissues, thereby producing strong cytotoxic action against a wide range of solid tumor types13, 14, 16, 21, 24, 25. This evidence concerns the gene PLAU and neoplasm.